obinutuzumab
BO21004 (Stage 1b)
Phase 3 small_molecule completed
Quick answer
obinutuzumab for Lymphocytic Leukemia, Chronic is a Phase 3 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hoffmann-La Roche
- Indication
- Lymphocytic Leukemia, Chronic
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed